Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
This expansion of the screening and multi-sub-study Lung-MAP trial is motivated by the changing landscape due to progress in the development of immunotherapies. The Lung-MAP trial was originally opened in June of 2014 for second-line treatment of participants with stage IV squamous lung cancer or squamous lung cancer that has come back (recurrent). The trial was amended to allow all participants with previously-treated stage IV or recurrent squamous lung cancer in 2015. The study is now expanding to allow participants with all types of previously-treated stage IV or recurrent non-small cell lung cancer. The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned in order to compare new targeted cancer therapy designed to block the growth and spread of cancer, with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes “non-match” sub-studies which will include all screened participants not eligible for any of the biomarker-driven sub-studies.
Inclusion Criteria
- Participants must have pathologically or cytologically proven non-small cell lung cancer (NSCLC). Mixed histologic subtypes of NSCLC are acceptable, but any known component of small cell lung cancer is not allowed
- Participants must have stage IV NSCLC, or recurrent or progressive NSCLC without a curative treatment option available
- Participants must be ≥ 18 years of age
- Participants’ most recent Zubrod/Eastern Cooperative Oncology Group (ECOG) performance status must be 0–2 and be documented within 28 days prior to registration
- Participants must be eligible to be pre-screened prior to progression or screened at progression or enrolled with treatment-naive NSCLC and a designated targetable alteration (if sub-studies allowing treatment-naive participants are open at the time of registration)
- To be eligible to be pre-screened, participants must have tumor tissue available for on-study biomarker profiling and must meet both of the following criteria: * Participants must be prior to progression on their current or most recent systemic treatment for stage IV or recurrent/progressive NSCLC, AND * Participants must have previously received or currently be receiving a first-line standard of care therapy for stage IV or recurrent/progressive NSCLC. Participants may have received multiple lines of therapy for stage IV or recurrent/progressive NSCLC * NOTE: Participants using previously completed biomarker test are not eligible to be pre-screened and must only register to be screened at progression * Sub-study assignments are provided for pre-screened participants when the LUNGMAP Notice of Progression Form is submitted in RAVE * Participants receiving osimertinib interested in participating in S1900G must not be pre-screened and will need a post-progression assessment of MET amplification status (on tissue or blood) due to the S1900G eligibility
- To be eligible to be screened at progression, participants must meet the following criteria for prior treatment of NSCLC. Specifically, participants: * Must have received at least one line of systemic standard of care therapy for stage I-IV NSCLC, AND * Must have progressed during or following their most recent line of systemic therapy for NSCLC, AND * If participant has not received any prior systemic therapy for stage IV or recurrent/progressive NSCLC, disease progression on prior systemic therapy for stage I-III disease must have occurred within (≤) 180 days from the last date that participant received that therapy. If disease progression was greater than (>) 180 days after the last dose of therapy for stage I-III disease, participants must receive standard-of-care therapy for stage IV or recurrent/progressive disease and experience disease progression during or after this therapy to be eligible
- To be eligible to be screened at progression, participants must meet one of the following criteria for biomarker testing: * Have tumor tissue available for on-study biomarker profiling, OR * Have documentation of a previously completed next generation sequencing (NGS) test on the list of approved tests (see the LUNGMAP NGS Testing Reference Page at http://www.swog.org/lung-map-resources), OR * Have documentation of a previously completed NGS test not on the list of approved tests, have submitted a report to LUNGMAPNGS@swog.org for review, and have an e-mail documenting the test is acceptable, OR * Have documentation of the presence of a specific biomarker (or set of biomarkers) for one of the biomarker-driven sub-studies open at the time of registration and have submitted a report to LUNGMAPNGS@swog.org with an e-mail documenting that the test is acceptable * NOTE: For participants with known EGFR mutation positive, MET amplification positive NSCLC that are screening for entry into S1900G, the tissue specimen must have been obtained after radiographic or clinical progression on osimertinib
- Enrolling with treatment-naive NSCLC and a designated targetable alteration * Participants with documentation of the presence of a specific biomarker (or set of biomarkers) for one of the biomarker-driven sub-studies open to treatment-naïve participants at the time of registration are eligible if participants meet the following criteria. Specifically, ** Participants must not have received any systemic therapy for stage IV or recurrent NSCLC, AND ** Participants must have documentation of the presence of a specific biomarker (or set of biomarkers) for one of the biomarker-driven sub-studies open to treatment-naïve participants at the time of registration through ONE of the following mechanisms: *** Participants must have documentation of a previously completed next generation sequencing (NGS) test on the list of approved tests, OR *** Participants must have documentation of a previously completed NGS test not on the list of approved tests, have submitted a report for review, and have an e-mail documenting the test is acceptable, OR *** Participants must have documentation of the presence of a specific biomarker (or set of biomarkers) for one of the biomarker-driven sub-studies open to treatment-naïve participants at the time of registration and have submitted a report with an e-mail documenting that the test is acceptable
- For participants submitting tissue for on-study biomarker profiling, all of the following criteria must be met: * A formalin-fixed and paraffin-embedded (FFPE) tumor block, or at least 12 unstained slides plus an hematoxylin and eosin staining method (H&E)-stained slide or 13 unstained FFPE slides 4-5 microns thick must be available for submission, AND * Participants must agree to have this tissue submitted to Foundation Medicine for common broad platform Clinical Laboratory Improvement Act (CLIA) biomarker profiling, AND * Participants must agree to have any leftover tissue (tissue that remains after biomarker testing) retained for the use of future correlative studies, AND * The tumor sample must have ≥ 20% tumor cells and ≥ 0.2 mm^3 tumor volume, AND * The tumor sample must not be from a bone biopsy unless the specimen is entirely soft tissue or has not been decalcified. All other sites of tumor are acceptable, given the specimen meets all requirements * NOTE: Liquid specimens like pleural fluid are acceptable if they meet cellularity requirements and are mounted on an FFPE block
- For participants providing documentation of a previously completed test on the list of approved tests/laboratories, ALL of the following criteria must be met: * The full biomarker report must be available to upload as source documentation in RAVE. * The report must provide documentation of the following: ** That the test was done on solid tumor tissue or blood (indicating which) ** That the original report date on or after September 1, 2019 * The participant must have consented to have these test results disclosed to Southwest Oncology Group (SWOG) Cancer Research Network
- For participants providing documentation of a previously completed test NOT on the list of approved labs, the test and associated documentation must meet ALL the following criteria: * The full biomarker report must be available to upload as source documentation in RAVE * The test must have been performed within a laboratory with CLIA, International Organization for Standardization (ISO)/International Electrotechnical Commission (IEC), College of American Pathologists (CAP), or similar certification * The report must show that the test was done on solid tumor tissue or blood (indicating which) * The full list of genes included in the test must either be documented on the report or documented separately. * The report must show that the original report date was on or after September 1, 2019 * The report and associated documentation must have been submitted to LUNGMAPNGS@swog.org for review and an e-mail response must have been received documenting that the test is acceptable * The participant must have consented to have these test results disclosed to SWOG Cancer Research Network
- For participants with a previously completed NGS test based on blood only, the test must provide documentation of the presence of at least one of the alterations listed on the LUNGMAP Genomic Alterations Form. If the report for blood-based NGS does not document the presence of at least one of these alterations, the participant is not eligible. To be eligible, the participant must either submit documentation of an approved tissue-based NGS test or submit tissue for on-study biomarker testing
- Participants must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines * NOTE: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Additional locations may be listed on ClinicalTrials.gov for NCT03851445.
Locations matching your search criteria
United States
Alabama
Birmingham
Daphne
Fairhope
Mobile
Saraland
Alaska
Anchorage
Fairbanks
Arizona
Goodyear
Kingman
Phoenix
Tucson
Arkansas
Jonesboro
Little Rock
California
Anaheim
Antioch
Arroyo Grande
Auburn
Baldwin Park
Bellflower
Berkeley
Beverly Hills
Burbank
Burlingame
Cameron Park
Carmichael
Castro Valley
Chico
Davis
Duarte
Dublin
Elk Grove
Fontana
Fremont
Fresno
Fullerton
Harbor City
Irvine
La Jolla
Lancaster
Loma Linda
Long Beach
Los Angeles
Martinez
Marysville
Mather
Modesto
Mountain View
Napa
Novato
Oakland
Ontario
Orange
Palo Alto
Panorama City
Rancho Cordova
Rancho Mirage
Redwood City
Richmond
Riverside
Rocklin
Rohnert Park
Roseville
Sacramento
Saint Helena
San Diego
San Francisco
San Jose
San Leandro
San Marcos
San Mateo
San Rafael
Santa Barbara
Santa Clara
Santa Cruz
Santa Rosa
South San Francisco
Stockton
Sunnyvale
Tarzana
Torrance
Truckee
Upland
Vacaville
Vallejo
Walnut Creek
Whittier
Woodland
Woodland Hills
Colorado
Aurora
Boulder
Centennial
Colorado Springs
Denver
Durango
Englewood
Fort Collins
Greeley
Highlands Ranch
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Pueblo
Thornton
Westminster
Connecticut
Derby
Fairfield
Guilford
Hartford
Meriden
New Britain
New Haven
North Haven
Orange
Stamford
Torrington
Trumbull
Waterbury
Waterford
West Haven
Delaware
Dover
Lewes
Milford
Millville
Newark
Rehoboth Beach
Seaford
Wilmington
District of Columbia
Washington
Florida
Aventura
Fort Lauderdale
Gainesville
Hollywood
Miami Beach
Pembroke Pines
Tampa
Weston
Georgia
Albany
Atlanta
Augusta
Braselton
Decatur
Duluth
Gainesville
Lawrenceville
Savannah
Snellville
Valdosta
Hawaii
Aiea
Ewa Beach
Honolulu
Kahului
Kailua
Lihue
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Alton
Aurora
Barrington
Bloomington
Burr Ridge
Canton
Carthage
Centralia
Chicago
Crystal Lake
Danville
DeKalb
Decatur
Dixon
Downers Grove
Effingham
Elgin
Eureka
Evanston
Galesburg
Geneva
Glenview
Grayslake
Harvey
Hazel Crest
Highland Park
Hines
Homer Glen
Kewanee
Lake Forest
Libertyville
Macomb
Mattoon
Maywood
Melrose Park
Mount Vernon
New Lenox
O'Fallon
Oak Lawn
Orland Park
Ottawa
Park Ridge
Pekin
Peoria
Peru
Princeton
Rockford
Shiloh
Silvis
Springfield
Urbana
Warrenville
Washington
Yorkville
Indiana
Fort Wayne
Indianapolis
Michigan City
Mooresville
New Albany
Richmond
Terre Haute
Iowa
Ames
Ankeny
Bettendorf
Boone
Cedar Rapids
Clive
Council Bluffs
Creston
Davenport
Des Moines
Fort Dodge
Iowa City
Jefferson
Marshalltown
Waukee
West Des Moines
Kansas
Chanute
Dodge City
El Dorado
Fairway
Great Bend
Hays
Independence
Kansas City
Kingman
Lawrence
Leavenworth
Liberal
Manhattan
McPherson
Newton
Olathe
Overland Park
Parsons
Pittsburg
Pratt
Salina
Topeka
Wellington
Westwood
Wichita
Winfield
Kentucky
Ashland
Bardstown
Corbin
Elizabethtown
Lexington
London
Louisville
Owensboro
Paducah
Richmond
Shepherdsville
Louisiana
Baton Rouge
Covington
Houma
New Orleans
Shreveport
Maine
Augusta
Bangor
Belfast
Biddeford
Brewer
Rockport
Sanford
South Portland
Maryland
Annapolis
Baltimore
Cumberland
Elkton
Gaithersburg
Kensington
Largo
Lutherville
Ocean Pines
Randallstown
Salisbury
Westminster
Massachusetts
Beverly
Burlington
Gloucester
Jamaica Plain
Lowell
Peabody
Springfield
Worcester
Michigan
Alma
Alpena
Ann Arbor
Battle Creek
Brighton
Brownstown
Canton
Caro
Chelsea
Clarkston
Clinton Township
Dearborn
Detroit
East China
Escanaba
Flint
Gladwin
Grand Rapids
Grosse Pointe Woods
Jackson
Kalamazoo
Lansing
Livonia
Macomb Township
Marlette
Midland
Mount Pleasant
Muskegon
Niles
Norton Shores
Novi
Pontiac
Reed City
Rochester Hills
Saginaw
Saint Joseph
Shelby Township
Southfield
Sterling Heights
Tawas City
Traverse City
Warren
West Bloomfield
West Branch
Wyandotte
Wyoming
Ypsilanti
Minnesota
Aitkin
Baxter
Bemidji
Brainerd
Burnsville
Cambridge
Coon Rapids
Crosslake
Deer River
Detroit Lakes
Duluth
Edina
Ely
Fergus Falls
Fosston
Hibbing
International Falls
Maple Grove
Maplewood
Minneapolis
Monticello
Moose Lake
New Ulm
Park Rapids
Pequot Lakes
Pine River
Princeton
Robbinsdale
Saint Louis Park
Saint Paul
Sandstone
Shakopee
Staples
Stillwater
Thief River Falls
Virginia
Waconia
Willmar
Woodbury
Worthington
Wyoming
Mississippi
Columbus
Grenada
Gulfport
Jackson
New Albany
Oxford
Southhaven
Missouri
Ballwin
Bonne Terre
Cape Girardeau
Chesterfield
Creve Coeur
Farmington
Joplin
Kansas City
Lee's Summit
North Kansas City
Osage Beach
Saint Joseph
Saint Louis
Saint Peters
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Havre
Helena
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Omaha
Nevada
Carson City
Henderson
Las Vegas
Pahrump
Reno
New Hampshire
Concord
Lebanon
Manchester
Nashua
New Jersey
Basking Ridge
Holmdel
Lakewood
Long Branch
Middletown
Montvale
Moorestown
Neptune
Red Bank
Voorhees
New Mexico
Albuquerque
Las Cruces
Rio Rancho
New York
Bronx
Buffalo
Commack
East Hills
Elmira
Glens Falls
Jamaica
New York
Rochester
Uniondale
West Harrison
West Islip
North Carolina
Asheboro
Asheville
Burlington
Cary
Clyde
Durham
Garner
Greensboro
Hendersonville
Kernersville
Mebane
Mount Airy
North Wilkesboro
Pinehurst
Raleigh
Reidsville
Stateville
Thomasville
Weaverville
Winston-Salem
North Dakota
Bismarck
Fargo
Jamestown
Minot
Ohio
Alliance
Beavercreek
Belpre
Boardman
Canton
Centerville
Chillicothe
Cincinnati
Cleveland
Columbus
Dayton
Delaware
Dublin
Findlay
Franklin
Gahanna
Greenville
Grove City
Kettering
Lancaster
Lima
Mansfield
Marietta
Marion
Marysville
Mayfield Heights
Mount Vernon
New Albany
Newark
Perrysburg
Portsmouth
Sandusky
Springfield
Steubenville
Sylvania
Toledo
Troy
Warren
Warrensville Heights
Westerville
Wilmington
Youngstown
Zanesville
Oklahoma
Lawton
Oklahoma City
Oregon
Baker City
Bend
Clackamas
Coos Bay
Hood River
Newberg
Ontario
Oregon City
Portland
Redmond
Salem
Pennsylvania
Allentown
Altoona
Beaver
Bethlehem
Bryn Mawr
Butler
Carlisle
Chadds Ford
Chambersburg
Collegeville
Cranberry Township
Danville
Dickson City
East Norriton
East Stroudsburg
Ephrata
Erie
Exton
Farrell
Gettysburg
Greensburg
Greenville
Hanover
Harrisburg
Hazleton
Indiana
Johnstown
Lebanon
Lewisburg
McKeesport
Mechanicsburg
Media
Monroeville
Moon Township
Mount Pleasant
Natrona Heights
New Castle
North Huntingdon
Paoli
Philadelphia
Pittsburgh
Pottstown
Sayre
Scranton
Seneca
Uniontown
Washington
West Mifflin
Wilkes-Barre
Williamsport
Wynnewood
York
Rhode Island
Westerly
South Carolina
Anderson
Bluffton
Boiling Springs
Charleston
Clinton
Easley
Gaffney
Greenville
Greer
Hilton Head Island
Seneca
Spartanburg
Union
South Dakota
Rapid City
Sioux Falls
Tennessee
Collierville
Cookeville
Memphis
Texas
Abilene
Amarillo
Dallas
Fort Worth
Houston
Lubbock
Richardson
Utah
American Fork
Cedar City
Logan
Provo
Saint George
Salt Lake City
Vermont
Berlin
Burlington
Saint Johnsbury
White River Junction
Virginia
Burke
Charlottesville
Chesapeake
Gloucester
Lynchburg
McLean
Mechanicsville
Midlothian
Newport News
Richmond
South Hill
Suffolk
Virginia Beach
Williamsburg
Winchester
Woodbridge
Washington
Aberdeen
Auburn
Bellevue
Bellingham
Centralia
Edmonds
Everett
Gig Harbor
Issaquah
Kennewick
Kirkland
Lacey
Longview
Mount Vernon
Port Townsend
Puyallup
Renton
Seattle
Sedro-Woolley
Silverdale
Spokane
Spokane Valley
Tacoma
Vancouver
Walla Walla
Yakima
West Virginia
Bridgeport
Charleston
Huntington
Martinsburg
Morgantown
Parkersburg
Wheeling
Wisconsin
Antigo
Appleton
Ashland
Brookfield
Burlington
Chilton
Chippewa Falls
Cudahy
Eau Claire
Fond Du Lac
Franklin
Germantown
Grafton
Green Bay
Hayward
Janesville
Kenosha
La Crosse
Ladysmith
Madison
Manitowoc
Marinette
Marshfield
Medford
Menomonee Falls
Mequon
Milwaukee
Minocqua
Mukwonago
New Richmond
Oconomowoc
Oconto Falls
Oshkosh
Racine
Rhinelander
Rice Lake
Sheboygan
Spooner
Stevens Point
Sturgeon Bay
Summit
Superior
Two Rivers
Waukesha
Wausau
Wauwatosa
West Allis
West Bend
Weston
Wisconsin Rapids
Wyoming
Cody
Sheridan
PRIMARY OBJECTIVE:
I. To determine eligibility for participation in the biomarker-driven and non-match sub-studies included within the Lung-MAP umbrella protocol, by testing participant specimens or collecting results of prior testing by protocol-approved biomarker assays.
SECONDARY SCREENING SUCCESS RATE OBJECTIVE:
I. To evaluate the percentage of participants assigned to a sub-study that register to a sub-study.
SECONDARY TRANSLATIONAL MEDICINE OBJECTIVE:
I. To summarize the prevalence of biomarkers either reported through previously completed tests or determined via on-study biomarker testing.
OUTLINE:
Participants undergo collection of tumor tissue samples or submit previous genomic profile testing results. Participants are then assigned to a biomarker-driven or non-match sub-study based on biomarker results of tumor tissue samples.
S1800A (NON-MATCH SUB-STUDY): Patients are randomized to 1 of 2 arms.
ARM A: Patients may receive docetaxel intravenously (IV) over 30-60 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, pemetrexed IV over 10 minutes on day 1 (non-squamous non-small cell lung cancer [NSCLC] patients only), or ramucirumab IV over 30-60 minutes combined with docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) scan or magnetic resonance imaging (MRI) scans and collection of blood samples throughout the trial.
ARM B: Patients receive ramucirumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI scans and collection of blood samples throughout the trial.
S1800D: Patients are randomized to 1 of 2 arms.
ARM A: Patients may receive standard of care consisting of docetaxel IV over 30-60 minutes on day 1 of each cycle; gemcitabine IV over 30 minutes on days 1 and 8 of each cycle; pemetrexed IV over 10 minutes on day 1 of each cycle; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and collection of blood samples throughout trial.
ARM B: Patients receive pembrolizumab IV over 30 minutes and nogapendekin alfa subcutaneously (SC) on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients then receive nogapendekin alfa SC on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and collection of blood samples throughout trial.
S1900A: Patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation receive rucaparib orally (PO) twice daily (BID) on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
S1900B (CLOSED TO ACCRUAL 5/01/2021) : Patients with RET fusion receive selpercatinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and undergo blood sample collection throughout the trial.
S1900C (CLOSED TO ACCRUAL 12/18/2020): Patients with STK11 somatic mutation or STK11 bi-allelic loss receive talazoparib PO daily and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and blood sample collection throughout the trial.
S1900E: Patients with KRAS G12C mutation receive sotorasib PO once daily (QD) on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI and collection of blood samples throughout the study.
S1900F: Patients with RET fusion are randomized to 1 of 2 arms.
ARM A: Patients receive carboplatin IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also selpercatinib PO BID in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans during screening and on study, and collection of blood samples on study.
ARM B: Patients receive carboplatin IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans during screening and on study, and collection of blood samples on study.
S1900K: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive ramucirumab IV over 30-60 minutes on day 1 of each cycle and tepotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo lymphoscintigraphy scan at screening prior to treatment, at the first occurrence of peripheral edema (defined as the development of grade ≥ 1 Common Terminology Criteria for Adverse Events [CTCAE] Edema Limbs affecting either the arms, hands, or legs), and if peripheral edema increases in attribution. Patients also undergo blood sample collection, CT scan and/or MRI throughout the trial. Additionally, patients undergo urine sample collection during screening and on study.
ARM B: Patients receive tepotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo lymphoscintigraphy scan at screening prior to treatment, at the first occurrence of peripheral edema (defined as the development of grade ≥ 1 CTCAE Edema Limbs affecting either the arms, hands, or legs), and if peripheral edema increases in attribution. Patients also undergo blood sample collection, CT scan and/or MRI throughout the trial. Additionally, patients undergo urine sample collection during screening and on study.
S1800E: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive dexamethasone PO BID on days 0-2, ramucirumab IV over 30-60 minutes on day 1 and docetaxel IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, and CT or MRI throughout the study.
ARM II: Patients receive dexamethasone PO BID on days 0-2, ramucirumab IV over 30-60 minutes on day 1, docetaxel IV over 60 minutes on day 1, and cemiplimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, and CT or MRI throughout the study.
S1900G: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive capmatinib PO BID, osimertinib PO QD, and ramucirumab IV over 30-60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.
ARM B: Patients receive capmatinib PO BID and osimertinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.
S1900J: Patients receive amivantamab hyaluronidase SC on days 1, 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and collection of blood samples throughout the trial.
After completion of study intervention, participants are followed up every 6 months for up to 3 years.
Trial PhasePhase II/III
Trial Typescreening
Lead OrganizationSWOG
Principal InvestigatorKaren Lynn Reckamp
- Primary IDLUNGMAP
- Secondary IDsNCI-2018-01540
- ClinicalTrials.gov IDNCT03851445